Unicycive Therapeutics, Inc.
No SEC Form 4 filings for $UNCY in the last 30 days.
See all $UNCY insider activity →Unicycive Therapeutics (UNCY) disclosed a securities class action lawsuit filed on September 3, 2026, in the Northern District of California. The lawsuit alleges violations of federal securities laws related to public statements about its oxylanthanum carbonate phosphate binder for treating hyperphosphatemia. The company states it believes the claims are meritless and plans to defend itself vigorously.
Unicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events . On September 3, 2026, a securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. (the “Company”) and certain of its officers. This action alleges violations of t
Unicycive Therapeutics, Inc. disclosed in an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC report beneficial ownership of 4,856,259 shares, or 9.99%, based on 27,855,257 shares outstanding as of Aug. 12, 2026. The stake includes 550,000 common shares plus conversion of Series A-3/A-4/A-5 preferred underlying warrants exercisable within 60 days.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning UNCY (Unicycive Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent UNCY coverage spans regulation, financial news and earnings.
The lawsuit introduces legal risk and potential liability, likely weighing on the stock.
The lawsuit introduces legal risk and could depress the stock.
A near-10% holder with sole voting power can increase governance influence and raise takeover or financing speculation risk.
The earnings beat and narrower loss improve near-term sentiment, but the FDA manufacturing inspection timing remains the key swing factor for OLC approval prospects.
The FDA inspection assignment is a concrete regulatory process step that can shorten or extend the path to OLC NDA resubmission and approval.
AlphAI scores every news story that mentions UNCY with an AI model for sentiment and relevance, and aggregates insider trades from Unicycive Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Unicycive Therapeutics (UNCY) disclosed a securities class action lawsuit filed on September 3, 2026, in the Northern District of California. The lawsuit alleges violations of federal securities laws related to public statements about its oxylanthanum carbonate phosphate binder for treating hyperphosphatemia. The company states it believes the claims are meritless and plans to defend itself vigorously.
2 min readUnicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events . On September 3, 2026, a securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. (the “Company”) and certain of its officers. This action alleges violations of t
1 min readUnicycive Therapeutics, Inc. disclosed in an amended Schedule 13G that Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC report beneficial ownership of 4,856,259 shares, or 9.99%, based on 27,855,257 shares outstanding as of Aug. 12, 2026. The stake includes 550,000 common shares plus conversion of Series A-3/A-4/A-5 preferred underlying warrants exercisable within 60 days.
3 min readUnicycive Therapeutics (NASDAQ:UNCY) shares rose about 2% premarket after it reported a Q2 loss of $0.06 per share versus a $0.48 consensus. Net loss was $1.7M, down from $6.5M, helped by $8.0M other income from warrant liability fair value changes. The FDA issued a Complete Response Letter for OLC, citing third-party manufacturing deficiencies; an inspection is scheduled and the company plans to resubmit. Cash: $61.4M, runway into 2027.
5 min readUnicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing ven
4 min readBiotech news roundup: Novartis (NVS) won EU approval for Itvisma for SMA; HUTCHMED (HCM) got China approval for ORPATHYS (savolitinib) in MET-amplified gastric cancer; Vertex (VRTX) expanded CASGEVY to children as young as 2; Unicycive (UNCY) received an FDA CRL for its CKD dialysis NDA; Ipsen (IPN.PA) agreed to buy Memo Therapeutics (~€700m) and Kartos ($450m).
7 min readKirby McInerney LLP said it is investigating potential federal securities-law claims against Unicycive Therapeutics (NASDAQ:UNCY). The firm cites Unicycive’s June 30, 2026 FDA second Complete Response Letter for oxylanthanum carbonate, tied to prior manufacturing deficiencies. Unicycive shares fell about 39% from $7.70 to $4.69 that day; no lawsuit has been filed.
3 min readUnicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001766140 0001766140 2026-06-19 2026-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report
3 min readUnicycive Therapeutics, Inc. (UNCY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001766140 0001766140 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readBronstein, Gewirtz & Grossman, LLC is investigating potential claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased securities before March 29, 2024. The investigation seeks to determine if Unicycive and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information and to assist with the investigation.
3 min read
